HC Wainwright Analysts Decrease Earnings Estimates for VNDA

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright dropped their Q1 2025 earnings estimates for shares of Vanda Pharmaceuticals in a report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.52) for the quarter, down from their prior forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at $0.22 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. The firm had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%.

Separately, StockNews.com assumed coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Down 1.3 %

VNDA opened at $4.49 on Thursday. Vanda Pharmaceuticals has a 52 week low of $3.71 and a 52 week high of $6.75. The business has a fifty day simple moving average of $4.60 and a 200-day simple moving average of $4.82. The firm has a market cap of $261.86 million, a P/E ratio of -14.03 and a beta of 0.74.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VNDA. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $1,296,000. Millennium Management LLC grew its stake in Vanda Pharmaceuticals by 67.4% during the 4th quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock worth $3,203,000 after purchasing an additional 269,183 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Vanda Pharmaceuticals during the 4th quarter worth about $1,221,000. Dimensional Fund Advisors LP raised its position in Vanda Pharmaceuticals by 10.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock valued at $11,920,000 after purchasing an additional 227,428 shares in the last quarter. Finally, Monaco Asset Management SAM boosted its stake in shares of Vanda Pharmaceuticals by 92.8% in the 4th quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock valued at $1,879,000 after buying an additional 188,836 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.